European Commission Approves BMS’ New Plaque Psoriasis Drug
Bristol Meyer Squib (BMS) has scored a win with the European Commission (EC) approval of Sotyktu, its new treatment for plaque psoriasis. The treatment would be the first of its kind, an oral allosteric tyrosine kinase inhibitor. The approval covers adults with moderate-to-severe psoriasis that may benefit from systemic treatment for the disease.
UCB’s Psoriasis Drug’s FDA Application on Pause Due to Facility Inspection Issues
The US Food and Drug Administration (FDA) has temporarily halted the approval process for UCB’s psoriasis drug bimekizumab on concerns [...]
Positive Results Announced for Bristol Meyer Squibb’s Plaque Psoriasis Trial
Bristol Meyer Squib (BMS) has released promising two-year results for deucravacitinib, its psoriasis therapeutic. The results show the drug was [...]
Amgen’s Biosimilar of Stelara Shows Promising Preliminary Results
New preliminary results show that Amgen’s biosimilar ABP 654 is effective in reducing psoriasis symptoms. ABP 654 is a biosimilar [...]
Highmark Enters Outcomes-based Contract for Anti-inflammatory Drug Cimzia
Highmark announced today that it entered into an outcomes-based agreement with UCB Inc. for its tumor necrosis factor blocking medication [...]
